UNLABELLED: The aim of this study was to report and analyze the rate of wound complications in patients treated for ovarian cancer with or without adjuvant bevacizumab. PATIENTS AND METHODS: Were included in a prospective cohort study, all the patients with advanced ovarian cancer who received adjuvant chemotherapy with or without bevacizumab in our center from April 2007 to January 2009. The patients were separated into a bevacizumab adjuvant therapy group (n=13) and a control group without bevacizumab (n=12). All the patients underwent upfront surgery and received standard chemotherapy (carboplatin with paclitaxel). The patients were examined every two months by a gynecological surgeon and underwent abdomino pelvic CT-scan regularly. RESULTS: Among the 25 patients included in the study, six experienced wound dehiscence (24%). Five out of these six patients had received bevacizumab in addition to standard chemotherapy (p=0.078). CONCLUSION: We report a high rate of wound complications in ovarian cancer patients receiving bevacizumab after surgery.
UNLABELLED: The aim of this study was to report and analyze the rate of wound complications in patients treated for ovarian cancer with or without adjuvant bevacizumab. PATIENTS AND METHODS: Were included in a prospective cohort study, all the patients with advanced ovarian cancer who received adjuvant chemotherapy with or without bevacizumab in our center from April 2007 to January 2009. The patients were separated into a bevacizumab adjuvant therapy group (n=13) and a control group without bevacizumab (n=12). All the patients underwent upfront surgery and received standard chemotherapy (carboplatin with paclitaxel). The patients were examined every two months by a gynecological surgeon and underwent abdomino pelvic CT-scan regularly. RESULTS: Among the 25 patients included in the study, six experienced wound dehiscence (24%). Five out of these six patients had received bevacizumab in addition to standard chemotherapy (p=0.078). CONCLUSION: We report a high rate of wound complications in ovarian cancerpatients receiving bevacizumab after surgery.
Authors: J G Messer; E J Castillo; A M Abraham; J M Jiron; R Israel; J F Yarrow; S Thomas; M C Reynolds; R D Wnek; M Jorgensen; N Wanionok; C Van Poznak; I Bhattacharyya; D B Kimmel; J I Aguirre Journal: Bone Date: 2019-11-07 Impact factor: 4.398
Authors: Harry D Bear; Gong Tang; Priya Rastogi; Charles E Geyer; Christine K Zoon; Kelley M Kidwell; André Robidoux; Luis Baez-Diaz; Adam M Brufsky; Rita S Mehta; Louis Fehrenbacher; James A Young; Francis M Senecal; Rakesh Gaur; Richard G Margolese; Paul T Adams; Howard M Gross; Joseph P Costantino; Soonmyung Paik; Sandra M Swain; Eleftherios P Mamounas; Norman Wolmark Journal: Ann Surg Oncol Date: 2016-11-18 Impact factor: 5.344
Authors: Kyunghee Noh; Lingegowda S Mangala; Hee-Dong Han; Ningyan Zhang; Sunila Pradeep; Sherry Y Wu; Shaolin Ma; Edna Mora; Rajesha Rupaimoole; Dahai Jiang; Yunfei Wen; Mian M K Shahzad; Yasmin Lyons; MinSoon Cho; Wei Hu; Archana S Nagaraja; Monika Haemmerle; Celia S L Mak; Xiuhui Chen; Kshipra M Gharpure; Hui Deng; Wei Xiong; Charles V Kingsley; Jinsong Liu; Nicholas Jennings; Michael J Birrer; Richard R Bouchard; Gabriel Lopez-Berestein; Robert L Coleman; Zhiqiang An; Anil K Sood Journal: Cell Rep Date: 2017-12-05 Impact factor: 9.423